Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

Per the terms of the agreement, both companies will develop and commercialize petrelintide, Zealand Pharma’s amylin analog, as a standalone therapy and in a fixed-dose combination with Roche’s ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

R.A.D. has received grants from Takeda and Amylin Pharmaceuticals and has been a board member of and consulted for Takeda, Amylin Pharmaceuticals, Isis Pharmaceuticals, and Boehringer Ingelheim.